Literature DB >> 16498428

SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

C Kimchi-Sarfaty1, W D Vieira, D Dodds, A Sherman, R J Kreitman, S Shinar, M M Gottesman.   

Abstract

SV40 vectors packaged in vitro (pseudovirions) are an efficient delivery system for plasmids up to 17.7 kb, with or without SV40 sequences. A truncated Pseudomonas exotoxin gene (PE38) was delivered into various human cells (HeLa, KB-3-1, human lymphoblastoids, and erythroleukemia cells), in vitro using pseudovirions. The number of viable cells was reduced significantly in the PE38-transduced cells. Human KB adenocarcinomas growing in mice were treated with intratumoral injection of PE38 packaged in vitro, and tumor size decreased significantly. Intraperitoneal treatments were as effective in reducing tumor size as intratumoral treatments. To check the viability of mock- or PE38-treated mice, every 4 days they were weighed, their blood was tested, and various tissues were screened for pathology. All parameters showed that the in vitro-packaged vectors, injected into tumors or intraperitoneally, caused no abnormalities in mice. The combined treatment of doxorubicin with in vitro-packaged PE38 reduced tumor size slightly more than each of the treatments separately. However, the combined treatment did not cause the weight loss seen with doxorubicin alone. These results indicate that SV40 in vitro packaging is an effective system for cancer gene delivery using two different routes of injection and in combination with chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498428      PMCID: PMC1482740          DOI: 10.1038/sj.cgt.7700943

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  36 in total

1.  In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer.

Authors:  Chava Kimchi-Sarfaty; Orly Ben-Nun-Shaul; Deborah Rund; Ariella Oppenheim; Michael M Gottesman
Journal:  Hum Gene Ther       Date:  2002-01-20       Impact factor: 5.695

2.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Authors:  R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

Review 3.  Use of bacteria as anticancer agents.

Authors:  K K Jain
Journal:  Expert Opin Biol Ther       Date:  2001-03       Impact factor: 4.388

Review 4.  Current progress in suicide gene therapy for cancer.

Authors:  Kazuyuki Yazawa; William E Fisher; F Charles Brunicardi
Journal:  World J Surg       Date:  2002-04-15       Impact factor: 3.352

Review 5.  Targeting tumors with non-viral gene delivery systems.

Authors:  Manfred Ogris; Ernst Wagner
Journal:  Drug Discov Today       Date:  2002-04-15       Impact factor: 7.851

6.  High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.

Authors:  Chava Kimchi-Sarfaty; Mili Arora; Ziv Sandalon; Ariella Oppenheim; Michael M Gottesman
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

7.  Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection.

Authors:  T Y Chen; H F Shang; T L Chen; C P Lin; C F Hui; J Hwang
Journal:  Appl Microbiol Biotechnol       Date:  1999-10       Impact factor: 5.560

8.  Development of DNA delivery system using Pseudomonas exotoxin A and a DNA binding region of human DNA topoisomerase I.

Authors:  T Y Chen; C T Hsu; K H Chang; C Y Ting; J Whang-Peng; C F Hui; J Hwang
Journal:  Appl Microbiol Biotechnol       Date:  2000-05       Impact factor: 5.560

Review 9.  Immunotoxins containing Pseudomonas exotoxin A: a short history.

Authors:  Ira Pastan
Journal:  Cancer Immunol Immunother       Date:  2003-03-06       Impact factor: 6.630

10.  A circularly permuted recombinant interleukin 4 toxin with increased activity.

Authors:  R J Kreitman; R K Puri; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 12.779

View more
  7 in total

1.  Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.

Authors:  Yan-Xiang Cheng; Gan-Tao Chen; Xiao Yang; Yan-Qing Wang; Li Hong
Journal:  Curr Med Sci       Date:  2018-04-30

2.  Effect of dsDNA on the Assembly Pathway and Mechanical Strength of SV40 VP1 Virus-like Particles.

Authors:  Mariska G M van Rosmalen; Chenglei Li; Adam Zlotnick; Gijs J L Wuite; Wouter H Roos
Journal:  Biophys J       Date:  2018-09-13       Impact factor: 4.033

3.  Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5'UTR.

Authors:  Cobra Moradian; Fatemeh Rahbarizadeh
Journal:  Onco Targets Ther       Date:  2019-10-25       Impact factor: 4.147

4.  Inhibition of multidrug resistance by SV40 pseudovirion delivery of an antigene peptide nucleic acid (PNA) in cultured cells.

Authors:  Benjamin Macadangdang; Ning Zhang; Paul E Lund; Andrew H Marple; Mitsunori Okabe; Michael M Gottesman; Daniel H Appella; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

Review 5.  In Vitro Assembly of Virus-Like Particles and Their Applications.

Authors:  Dinh To Le; Kristian M Müller
Journal:  Life (Basel)       Date:  2021-04-10

6.  Simian virus 40 vectors for pulmonary gene therapy.

Authors:  Luminita Eid; Zohar Bromberg; Mahmoud Abd El-Latif; Evelyn Zeira; Ariella Oppenheim; Yoram G Weiss
Journal:  Respir Res       Date:  2007-10-29

7.  High cooperativity of the SV40 major capsid protein VP1 in virus assembly.

Authors:  Santanu Mukherjee; Mahmoud Abd-El-Latif; Michal Bronstein; Orly Ben-nun-Shaul; Stanislav Kler; Ariella Oppenheim
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.